Remedy Robotics raises $62 million Series B led by DCVC
The financing will support clinical trials and regulatory development of its N1 endovascular robot.
Remedy Robotics has raised $62 million in Series B funding. DCVC led the round, joined by UC Investments, Skip Capital, Hostplus, Build Collective, Blackbird, Divergent Capital and KdT Ventures.
The company plans a pivotal trial with the University of California, further regulatory development and prototype deployments with clinical partners. Its N1 system combines robotics, AI and imaging for endovascular procedures. It remains under development and is unavailable for commercial sale.
Use of funds
Pivotal clinical trial
Regulatory development
Prototype deployment with clinical partners